Alnylam Pharmaceuticals(ALNY) - 2025 Q3 - Quarterly Results
Alnylam Pharmaceuticals(US:ALNY)2025-10-30 12:06Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress − Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – − Continued Broad Access and Balanced Utilization of AMVUTTRA Across A ...